The 20 Best Gallbladder Cancer Doctors Near Me in Ann Arbor, MI

Dr. Sahai is the Leader of the Gastrointestinal Medical Oncology Section and Associate Professor in the Division of Hematology-Oncology, Department of Internal Medicine. Dr. Sahai is also a member of the University of Michigan Rogel Cancer Center and Director of Tumor Response Assessment Core.Dr. Sahai attended medical school at the Government Medical College at Amritsar with the Baba Farid University of Health Science in India. He then completed his Masters in Clinical Epidemiology at Harvard School of Public Health followed by Internal Medicine residency training at University of Pittsburgh where he met his wife. He completed his fellowship in Hematology-Oncology at Northwestern University where he also served as the Chief Fellow. Subsequently, Dr. Sahai joined University of Michigan as Assistant Professor in Internal Medicine in 2013.Dr. Sahai is a clinician-scientist who sees patients within the Multidisciplinary Pancreatic and Liver Tumor programs. As a clinical investigator he is the Principal Investigator on several investigator-initiated clinical trials open across the U.S. His translational research program leverages the pancreaticobiliary cancer biobanks that he directs for the therapeutic investigation of novel compounds in patient-derived cell lines and xenograft models to help develop novel phase 1/2 investigator-initiated clinical trials. Dr. Sahai is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Familial Pancreatic Cancer, and Neuroendocrine Tumor.

Jessica Fried is a Radiologist and an Interventional Radiologist practicing medicine in Ann Arbor, Michigan. Dr. Fried is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Visceromegaly, Alcoholic Cirrhosis, Cholangiocarcinoma (Bile Duct Cancer), and Cirrhosis. Dr. Fried is board certified in Diagnostic Radiology.

Dr. Zalupski is an Professor of Medicine in the division of Medical Oncology at the UMMC. He completed medical school, an internal medicine residency and a medical oncology fellowship at Wayne State University in Detroit. Dr. Zalupski's clinical and research interest is in experimental therapeutics of gastrointestinal malignancies and sarcomas. He also serves as the medical director of the Multidisciplinary Pancreatic Cancer Clinic. Dr. Zalupski is rated as an Advanced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, Familial Pancreatic Cancer, and Pancreaticoduodenectomy. Dr. Zalupski is board certified in Internal Medicine and Medical Oncology.

Thomas Enzler, MD PhD, is an Assistant Professor in the Division of Hematology and Oncology. He received his Master of Science from ETH Zurich and his Medical Degree from University of Basel, Switzerland. After completion of residency in Internal Medicine at University Hospitals of Zurich and Basel, Dr. Enzler did a research fellowship at the Dana Farber Cancer Institute, Harvard Medical School, Boston. There, he worked on projects focusing on tumor immune surveillance and his work resulted in several publications and in a PhD ‘magna cum laude’ in Biochemistry/Immunology (Harvard Medical School Boston/Max Delbrueck Center Berlin). He then moved to University of California San Diego to study signaling pathways of cancer cells and immune cells. While there, he successfully obtained ECFMG certification prior to doing clinic and laboratory research at Stanford University. From California Dr. Enzler went to Germany to do a Hematology and Oncology fellowship at University of Goettingen and he received board certification in both in Germany and in Switzerland. Dr. Enzler decided to return to the U.S. and completed U.S. residency in Internal Medicine at University of Arizona in Tucson. Following U.S. residency training, Dr. Enzler completed fellowship in Hematology and Oncology at Columbia University Medical Center, New York, where he worked on several research projects on gastrointestinal cancers. Dr. Enzler is rated as an Advanced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Ductal Adenocarcinoma. Dr. Enzler is board certified in Internal Medicine, Medical Oncology, and Hematology.

Oxana Crysler is an Oncologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Crysler is rated as an Advanced provider by MediFind in the treatment of Gallbladder Cancer. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Familial Pancreatic Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Crysler is board certified in Medical Oncology.

Dr. Daniel Chang is a nationally and internationally recognized expert in radiotherapy for GI malignancies. His primary research interest is in advanced radiotherapy techniques, primarily with stereotactic body radiotherapy (SBRT). He has led several studies investigating and establishing the efficacy and safety for SBRT for these diseases for liver and pancreatic tumors. His other research interests include normal tissue tolerances, quality of life after radiotherapy, and combining radiotherapy with targeted agents. In addition, he has a strong interest in the use of radiotherapy, particularly in combination with systemic agents, in patients with metastatic disease. Another area of interest is in health care utilization for patients with metastatic disease and using machine learning and other approaches to optimize care during the end-of-life period.Dr. Chang is interested in developing novel modalities and technologies for delivering radiotherapy. He previously led the FDA trial that led to approval of PET-guided radiotherapy, which in broader terms, is called Biology-guided radiotherapy. In addition, he has experience with MR-guided radiotherapy, and he is interested in exploring the role of particle therapy and heave ion radiotherapy.Dr. Chang received his MD from Wayne State University in 2002 and completed his residency in Radiation Oncology at the University of Florida in Gainesville, Florida in 2007. He then joined the Department of Radiation Oncology at Stanford University from 2007-2022, having previously served as residency program director from 2012-2017 and the Vice Chair of Clinical Operations from 2017-2022 where he was also the Sue and Bob McCollum Professor in Radiation Oncology.Dr. Chang is a member of the American Society of Radiation Oncology (ASTRO), American Radium Society (ARS), and the American Society of Clinical Oncology (ASCO). He serves on the scientific committee for ASTRO, ASCO, and GI ASCO. He has authored or co-authored over 190 peer-reviewed publications for journals including Journal of Clinical Oncology, Journal of the National Cancer Institute, Clinical Cancer Research, Radiology, International Journal of Radiation Oncology, Biology, and Physics, Radiotherapy and Oncology, and Cancer. He served as the senior editor for the GI section of the International Journal of Radiation Oncology, Biology, and Physics from 2013-2017 and is currently on the editorial board for Practical Radiation Oncologysince 2020. He served on the Hepatobiliary Panel for the National Cancer Comprehensive Network (NCCN) guidelines from 2013-2022, helping to shape national guidelines for the work-up, diagnosis, and treatment of patients with hepatobiliary cancers. He is currently the track chair for the GI track for the ASTRO Annual Meeting Scientific Committee. He also serves on the Education Committee for the Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Track for the ASCO annual meeting starting in 2023. Dr. Chang is rated as an Advanced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Anal Cancer, Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), and Familial Pancreatic Cancer. Dr. Chang is board certified in Radiation Oncology.

Dr. Clifford S. Cho is the C. Gardner Child Professor of Surgery in the Division of Hepatopancreatobiliary and Advanced Gastrointestinal Surgery at Michigan Medicine.Dr. Cho is an Honors graduate of Brown University and AOA graduate of the Vanderbilt University School of Medicine. He completed his general surgery residency and transplantation immunology postdoctoral research fellowship at the University of Wisconsin, where he served as Chief Administrative Resident. He completed his surgical oncology fellowship at the Memorial Sloan-Kettering Cancer Center, where he served as Chief Administrative Fellow. He joined the faculty of the University of Wisconsin School of Medicine and Public Health in 2006, where he was promoted to Associate Professor with Tenure and named the Ronald and Patricia Kissinger Professor of Surgical Oncology. He served as Chief of the Division of Surgical Oncology, Associate Residency Program Director, and co-Director of the Gastrointestinal Disease Oriented Team in the University of Wisconsin Carbone Cancer Center before moving to the University of Michigan in 2016.Dr. Cho’s academic focus is on hepatopancreatobiliary and gastrointestinal malignancies, cancer immunology, and the mentorship of clinical and research trainees. He has lectured on these academic interests in over 15 national and international visiting professorships, and was named the James IV Traveler in 2014. He has published over 120 peer-reviewed manuscripts and book chapters and currently serves on the editorial boards of Surgery and the Journal of Gastrointestinal Surgery. He is the Principal Investigator of a VA Merit Review-funded cancer immunology laboratory that is working to understand cancer-induced T cell suppression, and to identify novel T cell-based strategies for cancer immunotherapy. His laboratory has been continuously funded since 2006 by extramural support from the Veteran’s Administration, National Institutes of Health, American College of Surgeons, and Central Surgical Association, and is a member of the VA Oncology Merit Review study section. He has held a number of national academic leadership positions and is a member of over 15 surgical societies, including the American Surgical Association, Society of Clinical Surgery, Society of University Surgeons, and Surgical Biology Club II. Dr. Cho is rated as an Advanced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Cho is board certified in Surgery.

Christopher Sonnenday, M.D., M.H.S., is the Darrell A. Campbell, Jr, M.D., Collegiate Professor of Transplant Surgery at the University of Michigan and Transplant Center Director for University of Michigan Health. He serves as Executive Vice Chair of the Department of Surgery, Surgical Director of Living Donor Liver Transplantation, and Surgical Director of the Multidisciplinary Liver Tumor Program for Michigan Medicine. He is a Professor in the Department of Surgery, Section of Transplantation, and Professor of Health Management and Policy at the School of Public Health. Dr. Sonnenday received his medical degree from Vanderbilt University in 1997, and completed his General Surgery residency at the Johns Hopkins University in 2005. While a research fellow in transplantation from 2000 to 2003, he completed a Masters of Health Sciences in Clinical Investigation at the Bloomberg School of Public Health. After completion of his residency, Dr. Sonnenday continued at Johns Hopkins as a Fellow in Surgical Oncology and Instructor of Surgery until 2006, and he completed a fellowship in abdominal transplant surgery at the University of Michigan in 2008. His primary academic and research interests include the study of frailty in liver transplant candidates, machine perfusion in liver transplantation, the overlap of transplant and oncology, quality collaboratives in transplantation, and leadership development in academic surgery.Clinical Specialization: Dr. Sonnenday's clinical interests focus on liver transplantation, hepatobiliary and pancreatic surgery, and general surgery procedures in patients with advanced liver disease. He sees patients in the Multidisciplinary Liver Tumor Clinic at the University of Michigan Rogel Cancer Center and the Transplant Clinic at the Taubman Center. Dr. Sonnenday is rated as an Advanced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Bile Duct Cysts, Liver Failure, Cholangiocarcinoma (Bile Duct Cancer), Liver Transplant, and Hepatectomy. Dr. Sonnenday is board certified in Surgery.

Dr. Ferguson is a Clinical Assistant Professor of Surgery in the Division of Hepato-pancreato-biliary Surgery. Following undergraduate studies in Molecular & Integrative Physiology at the University of Illinois, he earned an MD and a PhD in Cancer Biology at the University of Chicago. He completed a general surgery residency at the University of Chicago, where he served as an administrative chief resident and completed a medical education fellowship, followed by a clinical fellowship in complex general surgical oncology at Memorial Sloan Kettering Cancer Center. He is board-certified in general surgery and complex general surgical oncology.He has won numerous teaching awards at every stage of his career. He is the co-editor of Difficult Decisions in Surgical Oncology—An Evidence-Based Approach. He is active in the American College of Surgeons, Society of Surgical Oncology, Americas Hepato-Pancreato-Biliary Association, and Association for Surgical Education.Clinical Specialization: Dr. Ferguson's clinical expertise is in the management of cancers and premalignant conditions of the pancreas, liver, bile ducts, gallbladder, and stomach. Dr. Ferguson is rated as an Advanced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Bile Duct Cysts, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Ferguson is board certified in Surgery and Complex General Surgical Oncology.

Dr. William M. Sherk is a board-certified Vascular Interventional Radiologist specializing in venous, lymphatic, and aortic diseases. He is co-lead of the steering committee of the Frankel Cardiovascular Center Venous Health Program, a multidisciplinary team focusing on the care of patients with complex venous problems. Dr. Sherk completed training at the University of Michigan in Interventional Radiology, where he served as Chief Resident. After residency, he joined the faculty at University of Michigan in the division of Interventional Radiology. His research focuses on the diagnosis and multidisciplinary treatments of venous disease, including chronic venous occlusion, cancer-related venous obstruction, and pulmonary embolism. He currently serves as the Program Director for the Integrated Interventional Radiology residency. Dr. Sherk is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Retroperitoneal Fibrosis, Intussusception in Children, May Thurner Syndrome, SVC Obstruction, and Thrombectomy. Dr. Sherk is board certified in Interventional Radiology & Diagnostic Radiology.

Evan Glazer, MD, PhD, FACS, is the Clinical Director of the Pancreatic Cancer Program at Michigan Medicine and the Associate Director of Clinical Research in the Rogel and Blondy Center for Pancreatic Cancer. Dr. Glazer earned his medical degree and a master's degree in public health at the George Washington University in Washington, DC. Subsequently, he completed residency in general surgery and completed a PhD in Cancer Biology at the University of Arizona, in Tucson, AZ. Dr. Glazer completed an NIH funded T32 training fellowship at the M.D. Anderson Cancer Center in Houston, TX. He completed a fellowship in complex general surgical oncology at the H. Lee Moffitt Cancer Center in Tampa, FL. Dr. Glazer is board certified in complex general surgical oncology and general surgery. His clinical and research focuses are on pancreatic and liver malignancies.After completing fellowship in Tampa, Dr. Glazer joined the University of Tennessee Health Science Center in Memphis, TN, and rose in rank to Associate Professor. He served as program director of the complex general surgical oncology fellowship there as well as associate program director for research in the general surgery residency program. Dr. Glazer is a member of the American College of Surgeons, American Association for Cancer Research, Society of Surgical Oncology, Association of Academic Surgery, and American Society of Clinical Oncology. With a national reputation, he has served on the Hepatobiliary Panel and Pancreatic Adenocarcinoma Panel for the National Comprehensive Cancer Network. He has served numerous roles for the Society of Surgical Oncology. Dr. Glazer is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Liver Cancer, Fibrolamellar Carcinoma, Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Glazer is board certified in Surgery and Complex General Surgical Oncology.

Arathi Mohan is an Oncologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. She has been practicing medicine for over 10 years. Dr. Mohan is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Familial Pancreatic Cancer, and Stomach Cancer. Dr. Mohan is board certified in Internal Medicine and Medical Oncology.

Dr. Jeffrey Smerage is a hematologist/oncologist specializing in breast cancer. He received both a medical and doctoral degree from the University of Florida and then went on to residency training at the University of Virginia. In 2004, after completing a fellowship in hematology and oncology at the University of Michigan, Dr. Smerage joined the faculty of the Department of Internal Medicine and began his practice in the Breast Care Center. Dr. Smerage is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Smerage is board certified in Medical Oncology and Clinical Informatics.

Dr. Cuneo grew up in Northern California. He studied Biological and Environmental Engineering at Cornell University in Ithaca, NY. Dr. Cuneo received his Doctor of Medicine degree from Vanderbilt University School of Medicine in 2007 and completed an internship there in 2008. In 2008 he started his residency in Radiation Oncology at Duke University Medical Center. Dr. Cuneo has been an Assistant Professor in the Department of Radiation Oncology at the University of Michigan since 2012. Dr. Cuneo is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 35 other conditions, according to our data. His clinical expertise encompasses Anal Cancer, Pancreatic Cancer, Liposarcoma, Liver Cancer, and Pancreaticoduodenectomy. Dr. Cuneo is board certified in Radiation Oncology.

Dr. Hari Nathan is a board-certified complex general surgical oncologist and Associate Professor of Surgery with Tenure. Dr. Nathan completed both his undergraduate and medical education with honors at The Johns Hopkins University. He also completed advanced training in health services research and was awarded a PhD from The Johns Hopkins Bloomberg School of Public Health. Dr. Nathan completed his clinical residency training in general surgery at The Johns Hopkins Hospital. He subsequently completed a clinical fellowship in complex general surgical oncology at Memorial Sloan Kettering Cancer Center, where he also served as the Chief Administrative Fellow in Surgery. He joined the faculty of the University of Michigan in 2014. Clinical Specialization: Dr. Nathan's clinical focus includes the multi-disciplinary treatment of tumors of the pancreas, liver, bile duct, and stomach. He has particular interests in the treatment of liver metastases from colorectal cancer and directs Michigan Medicine’s Hepatic Artery Infusion Pump (HAIP) Program. He also serves as the Surgical Director of the Multidisciplinary Pancreatic Cancer Clinic, coordinating the efforts of a multidisciplinary team at the busiest pancreatic cancer program in Michigan. Dr. Nathan is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Nathan is board certified in Surgery and Complex General Surgical Oncology.

Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology.

Seth A. Waits, MD is a faculty member in the Section of Transplant Surgery. Dr. Waits received his medical degree from the University of Toledo in 2009. He completed his general surgery residency and abdominal transplant fellowship at the University of Michigan in 2018. While a research fellow in transplantation and general surgery from 2013-2015, he investigated quality improvement efforts across hospital collaboratives and looked for novel methods of surgical education. He is board certified by the American College of Surgeons and holds a certificate of completion of fellowship from the American Society of Transplant Surgeons. Clinical Specialization:Dr. Waits clinical focus is on liver and kidney transplants, benign and malignant disease of the liver and biliary tree and general surgery in patients with end-stage liver and kidney disease. Dr. Waits is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Liver Failure, End-Stage Renal Disease (ESRD), Cholangiocarcinoma (Bile Duct Cancer), Liver Transplant, and Kidney Transplant. Dr. Waits is board certified in Surgery.

Dr. Lawrence structured his career to prepare to be a physician scientist by obtaining both an MD and PhD. He initially pursued internal medicine and medical oncology, but ultimately settled on radiation oncology. He is board certified in all 3 areas. He has had an active clinical practice in radiation oncology for 30 years specializing in the treatment of patients with gastrointestinal malignancies and CNS tumors.Dr. Lawrence has focused his research career in two main areas. First, in collaboration with basic scientists he developed a laboratory program in chemotherapeutic radiation sensitizers and, more recently, has studied how to integrate molecularly targeted therapies. He collaborates with basic science faculty interested in translational research to investigate new combinations that can form the basis for rational clinical trials. The second area of focus involves the use of highly conformal radiation therapy in the treatment of brain and gastrointestinal cancers. In particular, he is focusing, in collaboration with medical physicists, radiologists, imaging scientists, and biologists, on the concept of adapting treatment to the individual patient response, assessed both by state-of-the-art imaging and plasma biomarkers.Dr. Lawrence is the author of over 300 peer-reviewed publications, and his work has been continuously supported by the National Cancer Institute for over 20 years. Dr. Lawrence is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Lawrence is board certified in Radiation Oncology, Medical Oncology, and Internal Medicine.

Dr. Nataliya Razumilava speaks English and Russian.Dr. Razumilava is a physician-scientist with a clinical and research expertise in biliary disorders (cholangiopathies) and liver cancer. She serves as the Associate Director of the Liver Tumor Program at the University of Michigan. After completion of her fellowships at the Mayo Clinic, Rochester, MN, Dr. Razumilava joined the University of Michigan in 2015 to develop a translational program focused on processes underlying inflammation-driven bile duct damage leading to bile duct regeneration as opposed to progression to fibrosis and cancer. Her research is funded by external (NIDDK, AASLD, AHA, Gilead) and internal awards. In additional to clinical care and research, she is actively involved in professional societies academic activities including education. Dr. Razumilava is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Fibrolamellar Carcinoma, Sclerosing Cholangitis, Cholangitis, Liver Cancer, and Liver Transplant. Dr. Razumilava is board certified in Gastroenterology and Transplant Hepatology.

I am a transplant hepatologist and clinical researcher committed to the care of patients with liver cancer and advanced liver disease. I serve as the Medical Director of the Multidisciplinary Liver Tumor Clinic and Medical Director of the Living Donor Liver Transplantation Program. I believe that patients should have an active voice in their care and I work jointly with patients to ensure that their needs are met. Dr. Parikh is rated as an Experienced provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Liver Cancer, Cirrhosis, Ascites, Liver Transplant, and Endoscopy. Dr. Parikh is board certified in Gastroenterology and Transplant Hepatology.